secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001628280-26-017230
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026
--------------------------------------------------------------------------------

- Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).
- Cash, equivalents, investments $258.3M; runway extended into Q1 2028 via disciplined spending, $23.7M escrow return.
- Pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL; interim futility analysis (MRD clearance, safety) planned April 2026.
- Phase 1 RESOLUTION trial of ALLO-329 (CD19/CD70 CAR T) in autoimmune diseases; proof-of-concept data expected June 2026.
- ALLO-316 TRAVERSE trial in RCC completed Phase 1b enrollment; exploring partnering opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026017230/0001628280-26-017230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026017230/allo-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer